Clinical Trial Detail

NCT ID NCT01512251
Title BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors University of California, San Francisco
Indications

melanoma

Therapies

Buparlisib + Vemurafenib

Age Groups: adult senior

Additional content available in CKB BOOST